Showing results (121-130 of 335) with videos related to

Sort By:
Pageof 34
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2024
Body Weight Gain Associated With Alectinib in Patients With ALK+ Non-Small Cell Lung Cancer: Pooled Analysis of Individual Patient Data From Four Prospective Clinical TrialsBarend J Sikkema, Sara J Baart, Marthe S Paats, et al.
Frontiers in Genetics|July 26, 2021
CYP3A4 Genotyping in Clinical Practice: Ready for Implementation?Tessa A M Mulder, Ruben A G van Eerden, Mirjam de With, et al.
European Urology|December 9, 2014
Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate CancerRobert J van Soest, Ellen S de Morrée, Charlotte F Kweldam, et al.
Pharmacogenetics and Genomics|January 18, 2013
Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycinLaure Elens, Annemieke J M Nieuweboer, Stephen J Clarke, et al.
Neuro-Oncology Advances|January 20, 2022
Landscape of driver gene events, biomarkers, and druggable targets identified by whole-genome sequencing of glioblastomasWesley S van de Geer, Youri Hoogstrate, Kaspar Draaisma, et al.
European Journal of Clinical Pharmacology|September 22, 2015
Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinomaMeta H M Diekstra, Xiaoyan Liu, Jesse J Swen, et al.
Clinical Pharmacokinetics|October 9, 2015
Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI SwitchLisette Binkhorst, Marjolein Bannink, Peter de Bruijn, et al.
Bioanalysis|December 15, 2015
Development and clinical validation of an LC-MS/MS method for the quantification of pazopanib in DBSRemy B Verheijen, Sander Bins, Bas Thijssen, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|April 15, 2022
Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancerNiels Heersche, G D Marijn Veerman, Mirjam de With, et al.
Oncotarget|May 3, 2018
Influence of aprepitant and localization of the patch on fentanyl exposure in patients with cancer using transdermal fentanylEvelien J M Kuip, Wendy H Oldenmenger, Martine F Visser-Thijs, et al.
Pageof 34